KDR and neoplasm: The small-molecule inhibitor cabozantinib inhibits the activity of multiple receptor tyrosine kinases, including MET and vascular endothelial growth factor receptor (VEGFR), resulting in the inhibition of tumour angiogenesis and metastasis.6